Biocon Limited has informed the Exchange regarding a press release dated December 13, 2025, titled "Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide".
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon's subsidiary, Biocon Biologics, has entered into a settlement and license agreement to commercialize biosimilar Aflibercept on a worldwide basis. Aflibercept is a biologic drug typically used in treating eye conditions and certain cancers, and the biosimilar version would compete with the innovator product. The settlement nature of the agreement suggests resolution of patent disputes, clearing the path for market entry. This expands Biocon Biologics' biosimilar portfolio and global footprint. Specific financial terms, partner details, and timelines were not disclosed in this filing.
Positive for Biocon shareholders — this adds a new revenue-generating product to Biocon Biologics' global biosimilar pipeline and validates its ability to strike global commercialization deals. The stock could see positive sentiment, though actual financial impact depends on undisclosed deal terms and market launch timelines.